Navigation Links
Perceptive Informatics Improves Clinical Trial Management With Enhanced TrialWorks(R) Solution

BOSTON, Oct. 15 /PRNewswire-FirstCall/ -- Perceptive Informatics, one of the industry's leading eClinical technology providers and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), announced today that it has enhanced its TrialWorks(R) solution, a specialized Clinical Trial Management System (CTMS) designed specifically for small and mid-size companies. The enhanced 2.1 version of the TrialWorks solution has updated functionality for reporting, data transfer, and analyzing study information. The system is also aligned with new requirements for uploading information to the website, a registry of federally and privately supported clinical trials conducted in the United States and around the world.

"To meet the unique needs of small and mid-size biopharmaceutical companies conducting more complex, global clinical programs, the new features of the TrialWorks system provide a greater degree of flexibility and configurability for these demanding studies," said Steve Kent, President of Perceptive Informatics. "Since CTMS tracks, manages, and reports on every aspect of a clinical study, we believe it is a critical component of an overall eClinical solution that is needed to maximize the productivity and efficiency of clinical research."

The TrialWorks solution, which is part of Perceptive Informatics' industry-leading eClinical capabilities, is integrated with other eClinical systems including Interactive Voice and Web Response Systems (IVRS/IWRS) and Electronic Data Capture (EDC). The TrialWorks solution provides full visibility into clinical trial information and helps to streamline processes. The system, which is built to meet specific needs of small and mid-size biopharmaceutical companies and their service providers, supports clinical trials of all sizes, from single site studies to multi-national programs. The TrialWorks solution provides comprehensive trial management data for the entire clinical team, from consolidated metrics for senior management to reports for project teams. It delivers relevant information to all study stakeholders, promotes operational and workflow standards, and helps to ensure timely investigator payments as well as accurate financial reporting. The system also provides online and offline access to clinical monitors.

New enhancements to the TrialWorks solution include:

-- "My Reports" - with over 175 standard reports tailored for key departments and an ad-hoc reporting component, this feature now allows users and project teams to more easily access and share frequently used reports, saving time and creating a more organized reporting environment

-- Compatibility with new requirements of the website, and ability to export files for import into

-- New options to classify studies, offering greater flexibility in grouping studies together, as well as enhancements for more detailed filtering and analysis of study information

Additionally, a new web interface for the Universal Data Transfer Tool, which can be used in conjunction with the TrialWorks solution, provides a more streamlined transfer of patient and visit data as well as Case Report Form (CRF) status from other systems.

The TrialWorks solution, previously part of the ClinPhone product portfolio, has been used for thousands of clinical trials. The system, which has a user-friendly and intuitive interface, can be rapidly implemented company-wide. The TrialWorks solution can be licensed and installed, or implemented as a hosted solution.

About Perceptive Informatics

Perceptive Informatics, a subsidiary of PAREXEL, is one of the industry's leading eClinical technology providers. Perceptive Informatics offers unprecedented access to innovative eClinical technologies and resources, providing clinical trial sponsors, CROs, and other service providers with the benefits of an extensive line of products and services throughout the entire clinical development lifecycle. In August, 2008 Perceptive was joined with ClinPhone plc, and the newly combined organization offers best-in-class eClinical software and services that increase the efficiency and productivity of clinical research. Perceptive's expansive product portfolio includes Interactive Voice and Web Response Systems (IVRS/IWRS,) Medical Imaging, Electronic Data Capture (EDC) systems, Clinical Trial Management Systems (CTMS) and Electronic Patient Reported Outcomes (ePRO) solutions, as well as eClinical systems integration and implementation services. For more information about Perceptive Informatics, visit


PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 69 locations throughout 52 countries around the world, and has approximately 8,800 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including ClinPhone; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the Fiscal Year ended June 30, 2008 as filed with the SEC on August 28, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward- looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.


Jennifer Baird, Rebecca Passo

Senior Director of Public Relations SHIFT Communications

PAREXEL International Tel: +617-779-1817

Tel: +781-434-4409 Email:


SOURCE PAREXEL International
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
2. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
3. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
4. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
5. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Tailored Clopidogrel Dosing Improves PCI Outcomes
8. Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
9. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
10. Gene Therapy Improves Vision in Patients with Congenital Retinal Disease
11. Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
Post Your Comments:
(Date:11/26/2015)... , 26 november 2015 AAIPharma ... de geplande investering aan van ten minste ... laboratoria en het mondiale hoofdkantoor in ... zal resulteren in extra kantoorruimte en extra ... de groeiende behoeften van de farmaceutische en ...
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
(Date:11/26/2015)... 26, 2015 ... ser potential att använda SyMRI för att ... för patienter med multipel skleros (MS) eller ... SyntheticMR AB för att kunna använda SyMRI ... Med SyMRI kan man generera flera konstrastbilder ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... way that they are handling security in light of the recent terrorist attacks in ... an attempt to stop an attack from reaching U.S. soil. Especially around special events ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... were," said an inventor from Hillside, N.J. "Many people catch diseases simply from ... that individuals will always be protected from germs." , He developed the patent-pending ...
(Date:11/27/2015)... ... ... Herpes-only dating community in the world, revealed that over 50% of its members are under ... under the age of 50 – or 67% of the population - are infected with ... infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of the ...
(Date:11/27/2015)... MINNEAPOLIS, Minn. (PRWEB) , ... November 27, 2015 ... ... you start failing. Secura Consultants has prided itself for not only fulfilling the ... best income protection solutions at an affordable price and providing top-tier customer service. ...
Breaking Medicine News(10 mins):